Stan B Kaye

Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance.

Alan Richardson, S. Kaye, A. Richardson, 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

Percy Ivy, Xavier Paoletti, Laurence Collette, 2014, European journal of cancer.

Identifying prognostic signatures in the blood of ovarian cancer patients.

Gerhardt Attard, S. Kaye, G. Attard, 2013, Gynecologic oncology.

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Jan Lubinski, Alan Ashworth, Susan Shanley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Mitch Dowsett, Gerhardt Attard, Johann S de Bono, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Alan Gordon, James Paul, Gordon C Jayson, 2004, Journal of the National Cancer Institute.

Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience

S. Kaye, L. R. Molife, B. Basu, 2012, Clinical Cancer Research.